Innovations in Pharmaceutical Technology (IPT)
IPT provides a platform for cutting-edge ideas, concepts, and developments shaping the future of pharmaceutical R&D.
Install App?
Innovations in Pharmaceutical Technology (IPT)
www.iptonline.com
This is how the Install App dialog will look like once your App goes live.
Founders Respond to Participant Needs to Drive Trial Retention
BERWYN, PA., Nov. 14, 2022 – Mural Health Technologies, Inc., a new global provider of clinical trials technology, today announced the launch of its new technology platform, Mural Link, which has been built to make it easy to be a participant in global clinical research studies. Among other planned participant-facing feature sets, Mural Link is excited to launch the industry’s next-generation participant payment technology, designed by Sam Whitaker, the inventor of the industry’s first participant payment technology product, the ClinCard. Mural Link’s payments technology is complimented by three other initial features sets, namely transportation, two-way messaging and participant feedback, which will help participants overcome existing barriers to enrolling in and remaining in clinical trials.
In 2008, Sam Whitaker founded Greenphire and invented the first participant payment technology, the ClinCard. Over the last 15 years, technologies have evolved and the world has changed how it operates. Since the ClinCard’s launch, there has been an undeniable shift to the digitization of all aspects of day-to-day life, including personal financial management, transportation, and communication. Individuals have also become increasingly empowered in their relationships with the parts of the healthcare ecosystem that they interact with in their daily lives. Unfortunately, although not surprising, clinical trial technology has not adapted to meet the needs of an evolving world and modern-day clinical research participants.
To address the existing disparity, Sam and the Mural Health team have built a platform that focuses all of its effort on improving the patient experience and assisting participant populations that struggle to engage with and remain in studies. Mural Link’s next-generation participant payment technology is strategically leveraged by the platform in order to introduce and deliver other features that benefit of both patients and their caregivers. All of the features of the Mural Link platform are designed to improve site level operations and deliver greater strategic value to sponsors beyond those offered by point-solutions delivering payments via prepaid debit card. Mural Health’s platform will also offer unique structures to benefit other eClinical technologies and CROs.
“This time, I am not thinking of the payment technology as the end-goal but rather as a strategic first step that will help Mural Health accomplish a much larger product vision and, consequently, have a more profound impact on the global patient population.” said Sam. “We want to improve participants’ experience in trials. We want to make it easy to be a part of a trial, so more diverse populations can enroll in and stay engaged after randomization. We have a big vision and our entire team is passionate about the journey that lies ahead.”
“Payments are important, but Mural Link is built to do much more than just deliver payment to participants. The platform also helps participants get to their appointment (transportation) without incurring expense, helps participants communicate with site personnel (secure two-way in-app communications), and empowers the participant by giving them a voice, to provide feedback, which quantifies satisfaction across the participant’s trial journey. Mural Link is the first product that will give the sponsor satisfaction and retention data in real time across all the sites in a study. The platform will empower the study to identify at-risk participants in order to proactively remediate issues and retain individuals who would otherwise drop out.”
Mural Health will be debuting its platform at the CNS Summit in Boca Raton, FL on November 17-20, 2022.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/ec4596b6-cc02-4c93-8bb1-66ceb94fbddd.png?optimizer=image&width=360&aspect_ratio=3:4)
Automata launches LINQ Cloud software to scale and manage lab automation from anywhere
24 May 2023 -- London, UK -- Automata, a leading company powering life science labs to fully automate their workflows, today launches LINQ Cloud: cutting-edge laboratory automation software. LINQ Cloud connects a lab’s physical and digital environment together, enabling life science organisations to scale while reducing the manual workload for scientists.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/18bff7dd-0e97-4096-8867-aa9304b4bbe2.png?optimizer=image&width=360&aspect_ratio=3:4)
Enhanced user experience with the latest release of Scitara’s iPaaS for science, now SOC2 certified
24 May 2023 -- Massachusetts, US -- Laboratory digital transformation pioneer, Scitara, announces new releases to its SOC 2-certified Digital Lab Exchange DLX cloud platform to improve the user experience, enhance instrument connectivity and deliver new automation to the lab.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/f99a5b68-5d67-4f3a-853b-604dcc5882c3.png?optimizer=image&width=360&aspect_ratio=3:4)
CatSci Launch New and Improved SmartPath, a Digital Risk Assessment Tool To Maximise SM Success
23 May 2023 -- Cardiff, UK -- CatSci, an award-winning innovation partner for medicines development, are proud to announce the launch of their new and improved SmartPath. SmartPath is an innovative digital risk assessment tool that highlights the risks de-railing users’ API success and offers tailored Smart mitigation strategies on the project, formulation and API properties.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/939428fa-14bd-4b75-8930-d685348835da.png?optimizer=image&width=360&aspect_ratio=3:4)
Sphere Fluidics updates brand identity to align with ambitious, global commercial growth strategy
23 May 2023 -- Cambridge, UK -- Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy.
![[object Object]](https://cdn.magloft.com/pwa-665/article/image/c79b699a-631c-4bfd-95ec-f38c8a60f665.png?optimizer=image&width=360&aspect_ratio=3:4)
Aurigene Pharma Services to expand biologics CDMO capacity with a new biomanufacturing facility
22 May 2023 -- Hyderabad, India -- Aurigene Pharmaceutical Services, a contract research, development and manufacturing services organisation and a step-down subsidiary of Dr Reddy's Laboratories, announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies and viral vectors.
1
Human-Centred Design: From Inception to Integration
IPT sat down with Dr Chris Vincent at PDD, to understand more about the digital innovations that are leading design and whether technologies like Extended Reality (XR) can be beneficial to the process
2
The Importance of Temperature Control in Pharmaceutical Analysis
As technology within the analysis sphere continues to evolve, temperature control is becoming increasingly important for drug discovery and research
3
Providing Support Throughout the Patient Journey
Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. How best can they be implemented?
